- Policy
- How GC Pharma obtained the copyright of Moderna vaccine?
- by Lee, Jeong-Hwan Mar 4, 2021 06:10am
- Moderna signed distribution agreement with GC Pharma for its COVID-19 vaccine in Korea, and GC Pharma has the final copyright. On the 26th, GC Pharma was a successful bidder as a domestic pharmaceutical company in charge of licensing and distribution of Moderna’s mRNA-1273 vaccine. GC Pharma's CEO Eun-cheol Huh bids for &8361;34.2 billio
- InterView
- There is still an unmet demand for antiviral drugs
- by Eo, Yun-Ho Mar 3, 2021 06:26am
- Currently, vaccines developed by AstraZeneca, Pfizer and others are a hot issue, but in the first half of last year, Remdesivir was ranked first as a keyword related to COVID-19. Gilead, the developer of Veklury (Remdesivir), is a pharmaceutical company specializing in antiviral drugs. It is leading and has pipelines in a variety of fields
- Company
- Generic approvals soar again despite new stepped pricing
- by Chon, Seung-Hyun Mar 3, 2021 06:24am
- Despite being seemingly suppressed by the revised drug pricing system, the number of approved generic is soaring again. Hundreds of Atozet and Januvia generics have entered the market and recorded the highest number generic approvals since May last year. In the second half of last year, the pharmaceutical companies had a vacant gap in new ap
- Company
- Spravato Nasal Spray can be prescribed at general hospitals
- by Eo, Yun-Ho Mar 3, 2021 06:23am
- Janssen's new depression drug Spravato can be prescribed at general hospitals. According to related industries, in addition to Big5 such as SMC and SNUH, Kyunghee University Hospital, Kyungpook National University Hospital, Pusan &8203;&8203;Paik Hospital, Chung-Ang University Hospital, Jeju National University Hospital, and Haeundae P
- Company
- 3 MSD vaccines to raise supply price at least by 15%
- by Mar 3, 2021 06:23am
- Three vaccines by MSD Korea&8212;Gardasil, Gardasil 9 and RotaTeq&8212;would raise their supply price from April. A pharmaceutical industry source told on Feb. 27 that MSD Korea has decided to raise the price of human papillomavirus (HPV) vaccines Gardasil and Gardasil 9 and a rotavirus vaccine RotaTeq. The new price would be implement
- Policy
- Pfizer vaccine can be administered over the age of 16 years
- by Lee, Tak-Sun Mar 3, 2021 06:23am
- The Central Pharmaceutical Affairs Review Committee, an expert advisory body for the MFDS, recommended the approval of Pfizer's COVID-19 vaccine. They gathered opinions that it is possible to administer them even over the age of 16. The MFDS explained the results by announcing the results of the Central Pharmaceutical Affairs Review Commi
- Company
- Boryung and Kwangdong overcome MM drug Pomalyst patent
- by Kim, Jin-Gu Mar 2, 2021 06:26am
- Boryung Pharmaceutical and Kwangdong Pharmaceutical have successfully evaded the composition patent on Celgene’s multiple myeloma treatment Pomalyst (Pomalidomide). Overcoming the biggest barrier to receive the preferential sales approval, the two South Korean companies can now release the generics early in January 2024, immediately aft
- Policy
- Will Kymriah be approved?
- by Lee, Tak-Sun Mar 2, 2021 06:25am
- The market approval of Kymriah by Novartis, a commercially available CAR-T (chimeric antigen receptor-T cell) treatment in the domestic market, is imminent. Kymriah is the first CAR-T treatment approved by the US FDA, and it applied for approval in Korea earlier last year. According to the industry on the 1st, Kymriah recently complete
- Company
- Viatris Korea downsizing and offering ERP?
- by Mar 2, 2021 06:25am
- Pfizer Upjohn and Mylan recently merged and kicked off a new subsidiary Viatris, but now the company is busy downsizing. While planning to globally restructure and let go of maximum 9,000 employees, the multinational company’s massive change is to also affect the South Korean branch. A month after the official launch in last November, V
- Company
- Celltrion wins lawsuit over Mabthera patent
- by Kim, Jin-Gu Mar 2, 2021 06:25am
- Celltrion finally won the patent dispute over Mabthera (Rituximab). Celltrion has been able to completely overcome the patent risk of Mabthera biosimilar Truxima by confirming the victory in the lawsuit that lasted more than five years. On the morning of the 25th, the Supreme Court ruled in an appeal for invalidation of patent registratio
